FierceBiotech ١٩ مايو ٢٠٢٦ Facing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up
FierceBiotech ١٩ مايو ٢٠٢٦ Incyte inks deal with Edison Scientific to train AI through drug discovery
FierceBiotech ١٩ مايو ٢٠٢٦ Merck inks Keytruda supply pact to support Exelixis’ colorectal cancer trial
FierceBiotech ١٩ مايو ٢٠٢٦ Lauxera Capital Partners raises a hefty €520M for health, medtech companies
FierceBiotech ١٩ مايو ٢٠٢٦ Herantis taps Indivi for digital biomarker tech in Parkinson’s disease trial
FierceBiotech ١٩ مايو ٢٠٢٦ Relay ‘full steam ahead’ on PI3K inhibitor fueled by first phase 2 data in blood vessel disorder
FierceBiotech ١٨ مايو ٢٠٢٦ Sanofi and Wave post AATD updates in race to end genetic disease’s 40-year new treatment drought
FierceBiotech ١٨ مايو ٢٠٢٦ BioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal
FierceBiotech ١٨ مايو ٢٠٢٦ After rare disease flop, cash-strapped Quince finds salvation in reverse merger
FierceBiotech ١٨ مايو ٢٠٢٦ Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
FierceBiotech ١٨ مايو ٢٠٢٦ Vincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators
FierceBiotech ١٨ مايو ٢٠٢٦ Boston Scientific funnels $1.5B into MiRus, with option to buy TAVR system
FierceBiotech ١٨ مايو ٢٠٢٦ Ohio Discovery Corridor is Attracting the World’s Best in Pediatric Research. Here’s Why
FierceBiotech ١٨ مايو ٢٠٢٦ Ipsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3
FierceBiotech ١٨ مايو ٢٠٢٦ Analysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial